Treating shingles after it appears doesn’t reduce increased stroke risk
American Stroke Association News Brief – Abstract 39, Session A6
Note: This news brief contains updated statistics not available in the abstract.
Embargoed until 4 a.m. CT/5 a.m. ET, Wednesday, Jan. 30, 2019
DALLAS, Jan. 30, 2019 — Stroke risk increased significantly in the days, weeks and months after shingles appeared, despite use of the shingles vaccine and antiviral therapy to treat it, according to preliminary research to be presented in Honolulu at the American Stroke Association’s International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
Centers for Disease Control and Prevention (CDC) researchers studied more than 35,000 Medicare fee-for-service beneficiaries who had been diagnosed with shingles, also known as herpes zoster, and acute ischemic stroke between 2007 and 2015. They analyzed whether having the shingles vaccine, Zostavax, as a treatment, antiviral therapy or both after shingles would impact patients’ stroke risk. They found that stroke incidence jumped by 61 percent within 14 days after shingles onset. The increased stroke risk remained elevated six months after shingles but diminished with time.
Researchers didn’t find any evidence that having the vaccine or taking antiviral therapy once shingles appeared helped to reduce the increased stroke risk. But the researchers suggest having the shingles vaccine might be the most effective way to prevent shingles-associated stroke risk.
Shingles is an often painful rash caused by the virus that causes chicken pox. Almost one in three people in the United State will develop shingles in their lifetime, according to CDC. The American Heart Association recommends adults over age 50 get the shingles vaccine. The new vaccine, Shingrix, approved by FDA in 2017 has shown to be more than 90 percent effective at preventing shingles. In this study, researchers examined the effect of the Zostavax shingles vaccine because Medicare data was not yet available for the Shingrix shingles vaccine. Zostavax efficacy declines over time and protection from shingles only lasts about 5 years with Zostavax.
Quanhe Yang, Ph.D., senior scientist, CDC
Note: Scientific presentation is 9:21 a.m. HT/2:21 a.m. ET, Wednesday, Feb. 6, 2019.
- Downloadable multimedia related to this news brief are on the right column of the link https://newsroom.heart.org/news/treating-shingles-after-it-appears-doesnt-reduce-increased-stroke-risk?preview=a6018f5df0df0f0f69cf4e690a29d581
- In-hospital infections increase odds of readmission for stroke patients
- For more news from AHA International Stroke Conference 2019, follow us on Twitter @HeartNews #ISC19.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at https://www.heart.org/en/about-us/aha-financial-information.
About the American Stroke Association
The American Stroke Association is devoted to saving people from stroke — the No. 2 cause of death in the world and a leading cause of serious disability. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat stroke. The Dallas-based association officially launched in 1998 as a division of the American Heart Association. To learn more or to get involved, call 1-888-4STROKE or visit StrokeAssociation.org. Follow us on Facebook and Twitter.
For Media Inquiries and ASA Expert Perspective: 214-706-1173
Karen Astle: 214-706-1392; email@example.com
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
Feb. 6-8, 2019: AHA News Media Office at the
Honolulu Convention Center: 808-792-6530